Xilio Therapeutics Inc (NASDAQ: XLO) is 10.99% higher on its value in year-to-date trading and has touched a low of $0.53 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The XLO stock was last observed hovering at around $1.17 in the last trading session, with the day’s loss setting it -0.11%.
Currently trading at $1.06, the stock is 23.16% and 8.84% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.66 million and changing -9.40% at the moment leaves the stock 10.59% off its SMA200. XLO registered 73.49% gain for a year compared to 6-month gain of 15.23%.
The stock witnessed a -16.54% loss in the last 1 month and extending the period to 3 months gives it a 1.92%, and is -28.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 18.37% over the week and 14.04% over the month.
Xilio Therapeutics Inc (XLO) has around 73 employees, a market worth around $48.50M and $4.62M in sales. Profit margin for the company is -1359.37%. Distance from 52-week low is 98.50% and -45.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-222.41%).
with sales reaching $3.3M over the same period.The EPS is expected to grow by 59.04% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
The shares outstanding are 43.96M, and float is at 16.85M with Short Float at 1.18%.
The top institutional shareholder in the company is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with over 3.79 million shares valued at $3.59 million. The investor’s holdings represent 13.5618 of the XLO Shares outstanding. As of 2024-06-30, the second largest holder is ROCK SPRINGS CAPITAL MANAGEMENT LP with 3.0 million shares valued at $2.85 million to account for 10.7595 of the shares outstanding. The other top investors are RIVERVEST VENTURE MANAGEMENT LLC which holds 1.44 million shares representing 5.1641 and valued at over $1.37 million, while FMR LLC holds 5.0008 of the shares totaling 1.4 million with a market value of $1.32 million.
Xilio Therapeutics Inc (XLO) Insider Activity
The most recent transaction is an insider sale by Frankenfield Christopher James, the company’s Chief Financial Officer. SEC filings show that Frankenfield Christopher James sold 6,954 shares of the company’s common stock on Jan 02 ’25 at a price of $0.98 per share for a total of $6841.0. Following the sale, the insider now owns 12421.0 shares.
Xilio Therapeutics Inc disclosed in a document filed with the SEC on Jan 02 ’25 that Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) sold a total of 1,803 shares of the company’s common stock. The trade occurred on Jan 02 ’25 and was made at $0.98 per share for $1774.0. Following the transaction, the insider now directly holds 3197.0 shares of the XLO stock.
Still, SEC filings show that on Dec 18 ’24, GILEAD SCIENCES, INC. (10% Owner) acquired 1,759,978 shares at an average price of $1.04 for $1.83 million. The insider now directly holds 9,105,451 shares of Xilio Therapeutics Inc (XLO).
